INTSbenzinga

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data In Sarcoma And An Overview Of Its Ongoing Global Randomized Phase 3 Sarcoma Trial In A Late-Breaking Session At The 2024 Annual Connective Tissue Oncology Society Meeting; Phase 1/2 Data Showed A Med

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on November 18, 2024 by benzinga